Anteris Technologies Global Corp.

Contributing Author

Recent Articles by Anteris Technologies Global Corp.

Nov-10	Anteris Technologies Announces Results for the Third Quarter of 2026 AVR GlobeNewswire
Nov-01	Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026 AVR GlobeNewswire
Oct-27	Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026 AVR GlobeNewswire
Oct-19	Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance AVR GlobeNewswire
Aug-31	Anteris to Present at September Healthcare Investor Conferences AVR GlobeNewswire
Aug-11	Anteris Technologies Announces Results for the Second Quarter of 2026 AVR GlobeNewswire
Jun-08	Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance AVR GlobeNewswire
May-13	Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors AVR GlobeNewswire
May-12	Anteris Announces Results for the First Quarter of 2026 AVR GlobeNewswire
May-05	Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial AVR GlobeNewswire
Apr-28	Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial AVR GlobeNewswire
Feb-26	Anteris Reports 2025 Financial Results and Provides Corporate Update AVR GlobeNewswire
Feb-23	Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays AVR +8.45% GlobeNewswire
Jan-22	Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises AVR +8.42% GlobeNewswire
Jan-22	Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock AVR +8.42% GlobeNewswire
Jan-20	Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering AVR +5.39% GlobeNewswire
Jan-20	Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic AVR +12.52% AVR +5.39% GlobeNewswire
Nov-17	Anteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves AVR GlobeNewswire
Nov-12	Anteris Announces Results for the Third Quarter of 2025 AVR GlobeNewswire
Nov-03	FDA Approves Anteris's DurAVR THV Global Pivotal Trial (the "PARADIGM Trial") AVR GlobeNewswire
Oct-28	Anteris DurAVR THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year AVR -7.84% AVR -8.71% GlobeNewswire
Oct-27	Anteris Technologies Announces First Patients Treated in DurAVR THV Global Pivotal Trial (the "PARADIGM Trial") AVR GlobeNewswire
Oct-27	Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR THV to be Presented at TCT 2025 AVR GlobeNewswire
Oct-15	Anteris Receives First European Regulatory Clearance to Commence DurAVR THV Global Pivotal Trial (the "PARADIGM Trial") AVR GlobeNewswire
Sep-19	Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders AVR GlobeNewswire
Sep-11	Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders AVR GlobeNewswire
Sep-04	Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders AVR GlobeNewswire
Aug-11	Anteris Announces Results for the Second Quarter of 2025 AVR AVR +6.00% GlobeNewswire
Jun-09	Anteris Appoints David Roberts and Gregory Moss to its Board of Directors AVR GlobeNewswire
May-13	Anteris Announces Results for the First Quarter of 2025 AVR AVR -9.89% GlobeNewswire

Anteris Technologies Global Corp.

Recent Articles by Anteris Technologies Global Corp.

Upgrade your Finviz experience